The global endometriosis market is anticipated to grow at a considerable CAGR of 3.0% during the forecast period (2021-2027). The market growth is mainly attributed to the increase in the prevalence of endometriosis disease across the globe. According to the reports of the World Health Organization (WHO), as of March 2021, endometriosis affects around 10% of the reproductive age women and girls across the globe. The number of total cases of endometriosis disease globally currently are accounted for around 190 million. Moreover, according to the reports of OASH (Office on Women’s Health), the disease is common among females of age between 30 and 40 and 1% of American women between 15 and 44 were affected by the disease in the US. In addition to this, it is highly likely that certain genes predispose women to develop the disease which may lead to a higher risk in the development of endometriosis if their mother or sister are also affected.
Browse the full report description of "Global Endometriosis Market Size, Share & Trends Analysis Report By Drug Type (Gonadotropins Releasing Hormone Agonists, Non-Steroidal Anti-Inflammatory Drug, Progestin, and Oral Contraceptive Pills), By Diagnosis (Ultrasound, Pelvic Exam, Laparoscopy, Magnetic Resonance Imaging (MRI), Hysteroscopy, and Sonohysterography), By Treatment (Hormonal Therapy and Pain Management), By Distribution Channel (Hospital Pharmacies, Drug Stores, Retail Pharmacies, Mail Order Pharmacies, and E-Commerce) Forecast, 2021-2027" at https://www.omrglobal.com/industry-reports/endometriosis-market
Government and non-government organizations support and approvals are also estimated to fuel the growth of the market. For instance, In December 2020, Myovant Sciences and Pfizer Inc. announced a collaboration to develop and commercialize relugolix, a once-daily, oral gonadotropin-releasing hormone (GnRH) receptor antagonist in oncology and women’s health in the US and Canada. Besides, in July 2018, AbbVie Inc. in cooperation with Neurocrine Biosciences, Inc., announced that they have received U.S. Food and Drug Administration (FDA) approval for ORILISSA (elagolix) for the management of moderate to severe pain associated with endometriosis. This oral treatment reduced three types of endometriosis pain namely daily menstrual pelvic pain, non-menstrual pelvic pain and pain with sex. In May 2018, Takeda Pharmaceuticals Co. Ltd. and ASKA Pharmaceuticals Co., Ltd. announced that they have agreed to permit endometriosis for Japan to maximize the product value of Takeda named relugolix (TAK-385).
Market Coverage
o By Drug Type
o By Diagnosis
o By Treatment
o By Distribution Channel
o North America
o Europe
o Asia-Pacific
o Rest of the World
Key questions addressed by the report
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
Global Endometriosis Market Report Segment
By Drug Type
By Diagnosis
By Treatment
By Distribution Channel
Global Endometriosis Market Report Segment by Region
North America
Europe
Asia-Pacific
Rest of the World
To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/endometriosis-market